Vision – and the expertise to match
For over three decades, Fujirebio has been at the forefront of neurological disease diagnostics, pioneering breakthrough solutions that have transformed the understanding and diagnosis of neurological conditions including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Today, Fujirebio stands as a trusted expert partner, offering unmatched capabilities from early biomarker discovery and research to routine clinical testing.
For clinicians, researchers, pharmaceutical companies, and industry partners, Fujirebio offers something unique: a partner with both the vision to see what’s possible and the expertise to make it happen. We are not just developing diagnostic tests: we are advancing the field of neurological diagnostics to support better patient outcomes.
Whether you are exploring novel blood or CSF biomarkers, developing new treatments for neurological conditions, or implementing cutting-edge neurological diagnostics in clinical practice, Fujirebio provides the expertise, Lumipulse® platform technology, and Contract Development and Manufacturing Organization (CDMO) capabilities to help you succeed. Together, we’re creating the future of neurological diagnostics – one breakthrough at a time.
Beyond Alzheimer’s disease: a broader vision
While Fujirebio is well-known for our pioneering work in Alzheimer’s disease diagnostics (including our landmark automated, FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic test for early Alzheimer’s disease detection), our vision extends across the full spectrum of neurodegenerative conditions. We are actively working on biomarker assays for Lewy body dementias and motor neuron diseases such as multiple sclerosis, and maintaining a broader neurological biomarker pipeline that addresses multiple related conditions where precision diagnosis and disease monitoring are becoming critical.
The Fujirebio Neuro Center of Excellence drives biomarker research and diagnostic development in a uniquely collaborative environment that welcomes input from experts and partners, both academic research institutions and industrial pharmaceutical companies, worldwide.
Your partner across the entire development journey
Fujirebio is also redefining what is possible in terms of developing new neurological diagnostic solutions through our Neuro Expert Toolbox (NExT) – a comprehensive biomarker development framework. This innovative approach enables CDMO partners and customers to leverage Fujirebio’s unique expertise for every stage of their biomarker needs – from early biomarker conceptualization and assay development through to validated diagnostic solutions and regulatory approval.
Unmatched neuro CDMO expertise
From biomarker discovery to regulatory submission, we provide CDMO partners with a comprehensive, end-to-end development pathway that is unmatched in the neurological diagnostics field. This end-to-end expertise, combined with our proven track record of successful international regulatory approvals, makes Fujirebio the partner of choice for diagnostics companies seeking to enter or expand within neurological and neurodegenerative diseases testing.
Thanks to our open business model, we are committed to advancing neurological diagnostics beyond our own Lumipulse® platform. Through strategic CDMO partnerships with leading diagnostic companies, we enable broader access to our validated blood and CSF biomarkers and expertise. This approach means that groundbreaking tests we develop and validate can reach more patients through multiple diagnostic platforms and channels, maximizing their impact on global healthcare.
